Cinryze regulatory update

Health Canada granted Priority Review to an NDS from ViroPharma for Cinryze for the treatment and pre-procedure and routine prevention of angioedema attacks in hereditary angioedema (HAE) patients ages 6 years and older. ViroPharma plans to submit the application before the end of the quarter and expects a decision from Health Canada later this year. Priority Review allows for a shortened review target of 180 days. ViroPharma markets the IV complement 1 (C1) esterase inhibitor in the EU for all 3 indications and in the U.S. for routine prophylaxis of acute attacks of HAE. ...